Peppi Prasit
Tempest Technologies (United States)(US)Fate Therapeutics (United States)(US)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Cancer, Hypoxia, and Metabolism, Peroxisome Proliferator-Activated Receptors, Eicosanoids and Hypertension Pharmacology, Diabetes Treatment and Management
Most-Cited Works
- → A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model(2010)259 cited
- → Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L(2000)127 cited
- → Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist(2010)126 cited
- → Design and Synthesis of Tri-Ring P3 Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K(2005)94 cited
- → A Novel Class of Nonpeptidic Biaryl Inhibitors of Human Cathepsin K(2003)82 cited
- → Practical Asymmetric Synthesis of a Potent Cathepsin K Inhibitor. Efficient Palladium Removal Following Suzuki Coupling(2003)55 cited